会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 73. 发明授权
    • Penicillanic and cephalosporanic derivatives, preparation thereof, and
pharmaceutical compositions containing same
    • 青霉烷和头孢菌素衍生物,其制备物和含有它们的药物组合物
    • US4362721A
    • 1982-12-07
    • US327058
    • 1981-12-03
    • Giorgio FerrariVittorio Vecchietti
    • Giorgio FerrariVittorio Vecchietti
    • A61K31/43A61K31/545A61K31/546A61P31/04C07D499/00C07D499/68C07D501/22C07D519/06C07H13/12A61K31/70C07H15/26
    • C07H13/12C07D499/00
    • There are disclosed penicillanic and cephalosporanic derivatives of the formula: ##STR1## wherein R is H or --OH; R.sub.1 is a carbohydrate hexose radical of 3-O-glucose, 6-O-galactose, 3-O-glucose acetals, 3-O-glucose ketals, 6-O-galactose acetals, and 6-O-galactose ketals, and R.sub.2 is: ##STR2## where R.sub.3 is H or an alkali or alkaline-earth metal. The preparation of the derivatives and pharmaceutical compositions containing same are also disclosed.A process according to the invention comprises reacting a compound of the formula ##STR3## with a hexose carbohydrate, in --OH protected form, in an aqueous medium, in the presence of a water-miscible organic solvent, in the presence of a base, the reaction product being optionally transformed into the derivative wherein R.sub.1 is a carbohydrate in the unprotected form by treatment with Lewis' acid or a hydrogen halide acid.The compounds according to the invention are used in pharmaceutical compositions useful for treatment of infections by gram-positive and gram-negative pathogenous bacteria.
    • 公开了下式的青霉素和头孢菌素衍生物:其中R是H或-OH;(I)其中R是H或-OH; R1是3-O-葡萄糖,6-O-半乳糖,3-O-葡萄糖缩醛,3-O-葡萄糖缩酮,6-O-半乳糖缩醛和6-O-半乳糖缩酮的碳水化合物己糖基,R2 是: + TR 其中R3是H或碱金属或碱土金属。 还公开了含有它们的衍生物和药物组合物的制备。 根据本发明的方法包括在水溶性有机溶剂的存在下,在碱的存在下,使式IMA的化合物与-OH保护形式的己糖碳水化合物在水性介质中反应, 反应产物任选地转化为衍生物,其中R1是未保护形式的碳水化合物,用路易斯酸或卤化氢酸处理。 根据本发明的化合物用于治疗革兰氏阳性和革兰氏阴性病原菌感染的药物组合物中。
    • 76. 发明授权
    • Production of N-substituted derivatives of 1-desoxy-nojirimycin
    • 1-脱氧 - nojirimycin的N-取代衍生物的制备
    • US4266025A
    • 1981-05-05
    • US97099
    • 1979-11-23
    • Gunther KinastMichael Schedel
    • Gunther KinastMichael Schedel
    • C12P17/12C07C271/16C07D211/46C07H13/12C12P19/26C12P19/44C12R1/01C12R1/15C12R1/645
    • C07H13/12C07C271/16C07D211/46C12P19/26
    • The invention relates to a process for the production of compounds of the formula ##STR1## in which R is hydrogen or optionally substituted alkyl, alkenyl, aralkyl or aryl, by microbiological transformation of ##STR2## follow by catalytic hydrogenation. The compounds obtained are useful for the treatment of diabetes, hyperlipoproteinaemia and adiposity which comprises aerobically cultivates, in the presence of an assimilable source of carbon nitrogen, at a temperature of 20.degree. to 45.degree. C. and pH between 2 and 10 and in the presence of an effective amount of a compound of the formula ##STR3## in which R has the above-given meaning and,R.sub.1 denotes an optionally substituted benzyl radical or an optionally substituted .beta.-alkenyl group,an aerobic microorganism or an extract of aerobic microorganism capable, in a nutrient medium containing a compound of the formula (X), or accumulating an amount of a compound of the formula ##STR4## in which R and R.sub.1 have the above-mentioned meanings andsubjecting the resulting compound of the general formula XI to catalytic hydrogenation.
    • 本发明涉及通过催化氢化随后的微生物转化制备式(I)化合物的方法,其中R是氢或任选取代的烷基,烯基,芳烷基或芳基。 。 所获得的化合物可用于治疗糖尿病,高脂蛋白血症和肥胖,其包括在可同化的碳氮源的存在下,在20°至45℃的温度和2至10之间的pH下进行有氧培养,并且在 存在有效量的式(X)化合物,其中R具有上述含义,R 1表示任选取代的苄基或任选取代的β-链烯基,需氧微生物或提取物 在含有式(X)化合物的营养培养基中,或者累积一定量的式(XI)化合物,其中R和R 1具有上述含义,并使所得的 通式XI的化合物进行催化氢化。